Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jules Quartly

Advertisement
Set Alert for Articles By Jules Quartly

Latest From Jules Quartly

A Safe Harbor For Biotechs? Ascletis, BeiGene Mark Early Wins For HK Exchange

The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

Hong Kong Commercial

New Rules Could Means IP Loss For Firms Doing R&D In China

Multinationals and M&A deals could be adversely affected by new measures in China that could delay or even block the export of intellectual property out of the country.

China Policy

Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased

The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.

 

Hong Kong Commercial

Hong Kong Leveraging Home Court Advantage For Chinese Biotechs

The biggest shakeup of the Hong Kong Stock Exchange for three decades could see biotech businesses and innovators turn from West to East when seeking listings, as shown by plans being made by two prominent Chinese bioventures.

China Hong Kong

Riding China’s Oncology Market: ‘Verticalization’ Best?

While there have been a number of positive changes in the operating and regulatory environment in China, pharmaceutical companies will still need a focused strategy to succeed in the country’s increasingly competitive but potentially lucrative oncology market, according to one expert.

China Cancer

Asia-Pacific Healthcare Investment Solid Despite Global Worries

Solid fundamentals in the Asia-Pacific healthcare market are continuing to attract significant investment and M&A activity with no signs of a slowdown, despite fears over China’s economic growth and negative factors in the wider global economy. Medtech, digital health and health services are all set to benefit, experts say.

Asia Pacific M & A
See All
Advertisement
UsernamePublicRestriction

Register